<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551300</url>
  </required_header>
  <id_info>
    <org_study_id>APCKD001</org_study_id>
    <nct_id>NCT04551300</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505 to Treat Hyperphosphatemia in Hemodialysis Patients</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Efficacy of Accelerated and Fixed Doses of VS-505 in Comparison With Sevelamer Carbonate to Treat Hyperphosphatemia in Chronic Kidney Disease Patients Receiving Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Alebund Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Alebund Pharmaceuticals Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the&#xD;
      tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer&#xD;
      Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic&#xD;
      kidney disease subjects receiving maintenance hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main body of this study has 5 intervention arms, 4 VS-505 treatment arms of various&#xD;
      dosage plus 1 active control arm of Sevelamer Carbonate, each consists 25 subjects. Prior to&#xD;
      this main part, a dose escalating cohort of 25 subjects is added to evaluate the tolerability&#xD;
      of VS-505 in Chinese patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 different dosages of VS-505 in Comparison with Sevelamer Carbonate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum phosphorus change from baseline to end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to serum phosphorus response，defined as serum phosphorus level decrease by 0.32 mmol/L（1 mg/dL）and serum phosphorus level below 1.78 mmol/L（5.5 mg/dL）</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The achievement rate of subjects with serum phosphorus in the target range 1.13-1.78 mmol/L（3.5-5.5 mg/dL）by the end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium change from baseline to end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ca×P change from baseline to end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iPTH change from baseline to end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum ferritin change from baseline to end of treatment</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of serious adverse events (SAEs)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>VS-505 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS-505 750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS-505 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS-505 2250mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate 1600mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-505</intervention_name>
    <description>4 dosages of experimental drug</description>
    <arm_group_label>VS-505 1500mg</arm_group_label>
    <arm_group_label>VS-505 2250mg</arm_group_label>
    <arm_group_label>VS-505 500mg</arm_group_label>
    <arm_group_label>VS-505 750mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Sevelamer Carbonate 1600mg</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with end stage renal disease who are receiving a stable hemodialysis regimen (3&#xD;
             times per week) with sufficient dialysis adequacy;&#xD;
&#xD;
          -  Serum phosphorus level range from &gt;1.94 mmol/L (6.0 mg/dL) to ≤3.23 mmol/L (10.0&#xD;
             mg/dL) at the end of washout phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant patient or scheduled kidney transplant, or change to peritoneal&#xD;
             dialysis, home hemodialysis or plan to relocate to another dialysis center during the&#xD;
             study period；&#xD;
&#xD;
          -  Serum phosphorus level is &lt;1.29 mmol/L（4.0 mg/dL) or &gt;2.42 mmol/L（7.5 mg/dL) at&#xD;
             screening, or documented to be &gt;3.23 mmol/L（10 mg/dL) within the latest three month&#xD;
             prior to screening (screening included);&#xD;
&#xD;
          -  Serum calcium level is &lt;8 mg/dL or &gt;11 mg/dL at the screening;&#xD;
&#xD;
          -  Serum immunoreactive parathyroid hormone (iPTH)&gt;1000 pg/mL at the screening;&#xD;
&#xD;
          -  History of hemochromatosis or serum ferritin value ≥1000 μg/L at screening；&#xD;
&#xD;
          -  Current clinically significant gastrointestinal (GI) disorder, or history of intestine&#xD;
             obstruction, gastrectomy or duodenectomy, or GI tract surgery within 12 weeks prior to&#xD;
             screening;&#xD;
&#xD;
          -  Poorly controlled hypertension, cardiovascular disorders, and history of&#xD;
             cerebrovascular disease or cardiovascular disease event within 24 weeks (6 months)&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhizheng Zhang, M.D.</last_name>
    <phone>+86 13520132971</phone>
    <email>zhizheng.zhang@alebund.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zuo, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Wang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical University</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanghui Li, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoxing Wang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xingtai Medical College</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huixiao Zheng, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junwei Yang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolan Chen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Liu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Jiangsu People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhua Liu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongli Lin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Zheng, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijie Yuan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Wang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Long, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang He, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

